Cancer of the endometrium

Brémond, A.; Bataillard, Anne; Thomas, Laurence; Jl, Achard; Fervers, Béatrice; Fondrinier, É.; Lansac, J.; Bailly, C; Hoffstetter, S.; Basuyau, Jean-Pierre; d'Anjou, J; Descamps, P.; Farsi, Fadila; Guastalla, Jean‐Paul; Laffargue, F; Rodier, J. F.; Vincent, P; Pigneux, J

doi:10.1054/bjoc.2000.1760

Cited by 31 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The latest French professional recommendations, concordant with ESMO recommendations, were published in November 2010. The previous follow-up recommendations for EC were similar and were published in 2000 (5).…”

mentioning

confidence: 84%

Adherence to Guidelines During Follow-up of Endometrial Cancer: Analysis of French Health Insurance Database

Phelippeau

Rouzier

Koskas

2018

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 84%

Adherence to Guidelines During Follow-up of Endometrial Cancer: Analysis of French Health Insurance Database

Phelippeau

Rouzier

Koskas

2018

View full text Add to dashboard Cite

show abstract

“…According to Brémond and al. (2001) 37 , Surgery is the standard treatment for endometrial cancer as long as the stage and patient's condition allow it. Standard surgery is a total hysterectomy with bilateral adnexectomy.…”

Section: Surgical Treatmentmentioning

confidence: 99%

Histo-Epidemiological Profile of Endometrial Cancer in the Oran Region

Fizazi

Bouzouina

Bouziani

et al. 2020

J. Drug Delivery Ther.

View full text Add to dashboard Cite

Objective: The aim of the present study is to describe the epidemiological, histopathological and therapeutic profile of endometrial cancers in the region of Oran. Methods: We conducted a retrospective study by exploring the medical files of 25 female patients diagnosed of endometrial cancer and treated at the level of the EHU November 1, 1954’s medical oncology department in Oran during the period from January 2015 to December 2019. For data collection, we used a structured exploitation sheet to obtain necessary information. Variables were analyzed using SPSS Software Version 20.0. Results: The median age of patients was 59 years with extremes ranging from 42 to 83 years. More than 56% of our patients were over 50 years old, 40% of the patients were nulliparous and 80% postmenopausal. The average age of menarche was 14.09 ± 1.44 years with extremes ranging from 12 to 17 years. The indication for anatomopathological examination was dominated by metrorrhagia (80%). Histopathologically, endometrioid adenocarcinoma was the most common at 75% of cases. We also note that 62.5% were classified in stage I and 37.5% in stage II. Myometrium infiltration was observed in 66.67% of cases. The basic treatment for endometrial cancer remains surgical. Conclusion: At the end of this work, we concluded that this pathology remains essentially that of postmenopausal women. Endometrioid adenocarcinoma was the most common histologic type. This study also revealed many risk factors for endometrial cancer, such as advanced age, hypertension and nulliparity. Keywords: Cancer, Endometrium, Epidemiology, Anathomopathology, Risk factors

show abstract

“…Despite this, certain features identify women with higher risk of recurrence: certain histological subtypes (e.g. papillary serous carcinoma, endometrioid carcinoma and clear cell carcinoma); high grade, deep invasion in the muscle of the uterus; tumour extending to the cervix; spread to lymphatic or blood vessels and extra-uterine disease (Bremond 2001).…”

Section: Description Of the Conditionmentioning

confidence: 99%

Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma

Vale

Tierney

Bull

et al. 2012

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

This review suggests that more-intense chemotherapy regimens may improve both OS and PFS for women with advanced or recurrent endometrial cancer. However, owing to inconsistencies between cytotoxic drug combinations that have been assessed in randomised trials to date, the optimum regimen has still to be defined. Future trials should aim to include measures of quality of life (QoL) and symptom control in addition to survival and progression outcomes.

show abstract

Cancer of the endometrium

Cited by 31 publications

References 0 publications

Adherence to Guidelines During Follow-up of Endometrial Cancer: Analysis of French Health Insurance Database

Adherence to Guidelines During Follow-up of Endometrial Cancer: Analysis of French Health Insurance Database

Histo-Epidemiological Profile of Endometrial Cancer in the Oran Region

Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma

Contact Info

Product

Resources

About